An Open-label, Dose Escalation Phase I/II Trial of a KSP Inhibitor Given as a Constant 24-Hour Infusion in Patients With Advanced Solid Tumors.

Trial Profile

An Open-label, Dose Escalation Phase I/II Trial of a KSP Inhibitor Given as a Constant 24-Hour Infusion in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2014

At a glance

  • Drugs MK 0731 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Feb 2010 Official Title amended as reported by ClinicalTrials.gov.
    • 14 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
    • 06 Jul 2007 Status changed dfrom recuiting to in progress, from NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top